1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort

作者：Ricky K Hsu, Michael Sension, Jennifer S Fusco, Laurence Brunet, Quateka Cochran, Gayathri Sridhar, Vani Vannappagari, Jean A van Wyk, Michael Wohlfeiler, Gregory Fusco · 发表于：Open Forum Infectious Diseases · 年份：2023 · DOI：10.1093/ofid/ofad500.059 · 被引用次数：20 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、HIV/AIDS Research and Interventions

Abstract Background Cabotegravir + rilpivirine (CAB+RPV) injections, the first complete long-acting (LA) antiretroviral therapy (ART) regimen, was approved by the FDA in January 2021 for ART-experienced people with HIV (PWH) who are virologically suppressed (VL < 50 copies/mL). Among individuals virologically non-suppressed (VL ≥ 30 copies/mL) at initiation, high rates of virologic suppression were observed in the demonstration project at Ward 86 for CAB+RPV LA. We observed CAB+RPV LA real-world utilization and effectiveness over the first 2 years of availability in the United States (US) in individuals with VL ≥ 50 copies/mL at initiation in the OPERA® Cohort. Methods All ART-experienced adults with VL ≥ 50 copies/mL at initiation who received their first CAB+RPV LA injection between 21Jan2021 and 28Feb2023 were followed until 25Mar2023. Discontinuation (ART switch or 2 consecutive missed doses) and confirmed virologic failure (CVF; 2 consecutive VLs ≥ 200 copies/mL or 1 VL ≥ 200 copies/mL + discontinuation after a VL < 50 copies/mL) were described, for all individuals with VL ≥ 50 copies/mL and for the subset with VL ≥ 200 copies/mL. Results Of 1843 ART-experienced PWH with ≥ 1 CAB+RPV injections, 229 (12%) had a VL ≥ 50 copies/mL at initiation. At baseline, they were a median of 41 (interquartile range: 32, 52) years of age, 31% female, 57% Black and 20% Hispanic. Injections started a median of 9 (4, 17) years after HIV diagnosis with a median viral load of 2...